Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional ImpactAnniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders. Presented in partnership with global data firm Statista, the inaugural ranking recognizes the top-performing publicly listed companies in the United States that have demonstrated exceptional growth, financial stability, and stock performance over the past five years.
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the YearFREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. The annual program, conducted by leading independent market intelligence organization BioTech Breakthrough, recognizes innovative life sciences and biotechnology companies, products, and services worldwide. This year’s competition drew thousands of nominations from more than 15 countries.
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow CytometrySupports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive GrowthFREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences District. This relocation is an expansion, which reflects Cytek’s commitment to the EMEA region and highlights the company’s ongoing investment in delivering world-class solutions, training, and support to researchers and clinicians worldwide.
Cytek Biosciences Reports First Quarter 2025 Financial ResultsFREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 and remain in effect until December 31, 2025 unless extended or shortened by the Board of Directors.
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramFREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted thousands of nominations from 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
